Minerva Neurosciences | NERV - Ordinary Share Capital


Minerva Neurosciences reported $1000 in Ordinary Share Capital for its fiscal quarter ending in September of 2024.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Adma Biologics USD 232.29M 5.59M Mar/2026
ALKERMES USD 166.46M 855K Mar/2026
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
AstraZeneca USD 1.55B 73K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Cipla INR 807.78M 17K Mar/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.55M 1000 Mar/2026
CSL USD 482.13M 93.87M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Grifols EUR 680.58M 846.11K Dec/2025
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
J&J USD 2.41B 1.74M Dec/2025
Merck USD 2.47B 12.72M Dec/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 13M Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sanofi EUR 1.21B 8.25M Mar/2026
Takeda JPY 1.58B 241K Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024